Modality
Gene Therapy
MOA
SOS1i
Target
SMN2
Pathway
Notch
CLLNSCLCRett
Development Pipeline
Preclinical
Apr 2019
→ Feb 2027
PreclinicalCurrent
NCT05987952
1,361 pts·Rett
2019-04→2027-02·Active
1,361 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-0610mo awayInterim· Rett
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Active
Catalysts
Interim
2027-02-06 · 10mo away
Rett
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05987952 | Preclinical | Rett | Active | 1361 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |